These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 21149626)

  • 1. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study.
    Farrell DJ; Robbins M; Rhys-Williams W; Love WG
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1177-81. PubMed ID: 21149626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and molecular characterization of methicillin-resistant Staphylococcus aureus with mupirocin, fusidic acid and/or retapamulin resistance.
    Chen W; He C; Yang H; Shu W; Cui Z; Tang R; Zhang C; Liu Q
    BMC Microbiol; 2020 Jun; 20(1):183. PubMed ID: 32600253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.
    Woodford N; Afzal-Shah M; Warner M; Livermore DM
    J Antimicrob Chemother; 2008 Oct; 62(4):766-8. PubMed ID: 18567573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.
    Candel FJ; Morales G; Picazo JJ
    Rev Esp Quimioter; 2011 Sep; 24(3):127-30. PubMed ID: 21947094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center.
    Harrington AT; Black JA; Clarridge JE
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1298-303. PubMed ID: 26666950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli.
    D'Lima L; Friedman L; Wang L; Xu P; Anderson M; Debabov D
    Antimicrob Agents Chemother; 2012 May; 56(5):2753-5. PubMed ID: 22354299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor alters the membrane of
    Leeten K; Jacques N; Esquembre LA; Schneider DC; Straetener J; Henriksen C; Musumeci L; Putters F; Melo S; Sánchez-López E; Giera M; Penoy N; Piel G; Verlaine O; Amoroso A; Joris B; Slavetinsky CJ; Goffin E; Pirotte B; Frees D; Brötz-Oesterhelt H; Lancellotti P; Oury C
    mBio; 2024 Oct; 15(10):e0132224. PubMed ID: 39311589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retapamulin Activity Against Pediatric Strains of Mupirocin-resistant Methicillin-resistant Staphylococcus aureus.
    Patel AB; Lighter J; Fulmer Y; Copin R; Ratner AJ; Shopsin B
    Pediatr Infect Dis J; 2021 Jul; 40(7):637-638. PubMed ID: 33657598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
    Kosowska-Shick K; Clark C; Pankuch GA; McGhee P; Dewasse B; Beachel L; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children.
    McNeil JC; Hulten KG; Kaplan SL; Mason EO
    Antimicrob Agents Chemother; 2014 May; 58(5):2878-83. PubMed ID: 24614375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
    Rio-Marques L; Hartke A; Bizzini A
    Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin.
    Fujimura S; Nakano Y; Watanabe A
    J Infect Chemother; 2014 Dec; 20(12):752-6. PubMed ID: 25287155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
    Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE
    J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets.
    Loeffler A; Baines SJ; Toleman MS; Felmingham D; Milsom SK; Edwards EA; Lloyd DH
    J Antimicrob Chemother; 2008 Dec; 62(6):1301-4. PubMed ID: 18819974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.
    Sader HS; Fey PD; Limaye AP; Madinger N; Pankey G; Rahal J; Rybak MJ; Snydman DR; Steed LL; Waites K; Jones RN
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4127-32. PubMed ID: 19635961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.
    Saravolatz LD; Pawlak J; Johnson L; Bonilla H; Saravolatz LD; Fakih MG; Fugelli A; Olsen WM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4478-82. PubMed ID: 22585222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
    Sader HS; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Antimicrobial Activities of Fusidic Acid and Retapamulin against Mupirocin- and Methicillin-Resistant Staphylococcus aureus.
    Park SH; Kim JK; Park K
    Ann Dermatol; 2015 Oct; 27(5):551-6. PubMed ID: 26512169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.